Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.

Sees 2024 revenue $4.0B-$4.2B, consensus $4.1B.

Reports Q1 revenue $901.98M, consensus $953.9M. "In Q1, we delivered combined double-digit year-over-year growth from our key growth drivers: Xywav, Epidiolex and Rylaze. We also significantly advanced our zanidatamab program with the completion of the BLA for 2L BTC," said CEO Bruce Cozadd. "We believe the robust growth in patients benefitting from Xywav underscores the appreciation physicians and patients have for the long-term health benefits of reducing sodium and expect Xywav to remain the oxybate of choice. We see continued demand for Rylaze as the only non-E. coli asparaginase regimen that provides sustained activity throughout the course of treatment, and we expect continued growth of Epidiolex to be driven by geographic expansion, optimized dosing and data demonstrating its beyond-seizure benefits. Growing and durable revenues from Xywav, Epidiolex and Rylaze, coupled with our pipeline progress, drive our confidence in delivering on our guidance and objectives for 2024."

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Deciphera Pharmaceuticals... To see the rest of the story go to thefly.com. See Story Here

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's... To see the rest of the story go to thefly.com. See Story Here

Incyte is maintaining its full year 2024 revenue and expense guidance. Incyte's guidance is summarized below. Guidance does not include revenue from any potential new product launches or the impact of the acquisition of Escient Pharmaceuticals or any other potential future strategic transactions. Sees Jakafi net product revenues $2,690 - $2,750M...

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Guggenheim downgraded Deciphera to Neutral from Buy with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Deciphera shares are set to resume trading at 7:30 am ET, with quotation to resume at 7:25 am ET, according to Nasdaq. Shares had been halted, pending news, ahead of the company announcing that it has entered into a definitive merger agreement with ONO Pharmaceutical, under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash.